Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 54% below Graham Number ($13.69) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 99.9% with 11.9% net margin
- High dividend yield of 9.6%
Organon & Co. (OGN) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $1.6 billion . Key value metrics: P/E ratio 2.2, P/B ratio 2.17, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Organon & Co. — Fundamental Analysis Summary
Organon & Co. (OGN) is trading 54% below its Graham Number of $13.69 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.2x.
On financial health, OGN shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 99.9% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 11.52.
StockPik's composite Value Score for OGN is 93/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
OGN shows revenue declining at 3% year-over-year, with earnings declining at 78%.
OGN pays a high dividend yield of 9.6%.